Blockade of TNF-α Decreases Both Inflammation and Efficacy of Intrapulmonary Ad.IFNβ Immunotherapy in an Orthotopic Model of Bronchogenic Lung Cancer

Molecular Therapy

Volumn 13, Issue 5, 2006, Pages 910-917

  Wilderman, Michael J ^a   Kim, Samuel ^a   Gillespie, Collin T ^a   Sun, Jing ^a   Kapoor, Veena ^a   Vachani, Anil ^a   Sterman, Daniel H ^a   Kaiser, Larry R ^a   Albelda, Steven M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adenovirus; anti TNF antibody; gene therapy; immunotherapy; innate immunity; interferon ; lung cancer; lung inflammation; orthotopic model

Indexed keywords

ADENOVIRUS VECTOR; BETA INTERFERON; CANCER ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BRONCHUS CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFICACY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INNATE IMMUNITY; LOBAR PNEUMONIA; LUNG CANCER; MOUSE; NONHUMAN; RAT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CARCINOMA, BRONCHOGENIC; GENETIC VECTORS; IMMUNOTHERAPY; INTERFERON-BETA; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PNEUMONIA; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; ANIMALIA;

EID: 33645870135     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.12.012     Document Type: Article

References (41)

1. Marr R.A., Addison C.L., Snider D., Muller W.J., Gauldie J., and Graham F.L. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther. 4 (1997) 1181-1188
2. Slos P., De Meyer M., Leroy P., Rousseau C., and Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther. 8 (2001) 321-332
3. Bramson J.L., Hitt M., Addison C.L., Muller W.J., Gauldie J., and Graham F.L. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7 (1996) 1995-2002
4. Odaka M., et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res. 61 (2001) 6201-6212
5. Odaka M., et al. Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol. Ther. 6 (2002) 210-218
6. Xu L., Xie K., and Fidler I.J. Therapy of human ovarian cancer by transfection with the murine interferon beta gene: role of macrophage-inducible nitric oxide synthase. Hum. Gene Ther. 9 (1998) 2699-2708
7. Cao G., et al. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther. 8 (2001) 497-505
8. Izawa J.I., et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin. Cancer Res. 8 (2002) 1258-1270
9. Sakurai F., et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I:poly C in a murine lung metastasis model. Cancer Gene Ther. 10 (2003) 661-668
10. Qin X.Q., et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA 95 (1998) 14411-14416
11. Lu W., Fidler I.J., and Dong Z. Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus-mediated interferon beta gene therapy. Cancer Res. 59 (1999) 5202-5208
12. Natsume A., Mizuno M., Ryuke Y., and Yoshida J. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther. 6 (1999) 1626-1633
13. Nakanishi H., et al. Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma. Clin. Cancer Res. 9 (2003) 1129-1135
14. Nakahara N., Pollack I.F., Storkus W.J., Wakabayashi T., Yoshida J., and Okada H. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther. 10 (2003) 549-558
15. Tada H., et al. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J. Clin. Invest. 108 (2001) 83-95
16. Sterman D.H., and Albelda S.M. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 10 (2005) 266-283
17. +T cell-mediated effects. Cancer Res. 65 (2005) 8379-8387
18. Jackson E.L., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15 (2001) 3243-3248
19. Barsky S.H., Cameron R., Osann K.E., Tomita D., and Holmes E.C. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 73 (1994) 1163-1170
20. Gandara D.R., et al. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin. Cancer Res. 10 (2004) 4205s-4209s
21. Hege K.M., and Carbone D.P. Lung cancer vaccines and gene therapy. Lung Cancer 41 Suppl. 1 (2003) S103-S113
22. Muruve D.A. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15 (2004) 1157-1166
23. Otake K., Ennist D.L., Harrod K., and Trapnell B.C. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum. Gene Ther. 9 (1998) 2207-2222
24. Zsengeller Z., Otake K., Hossain S.A., Berclaz P.Y., and Trapnell B.C. Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J. Virol. 74 (2000) 9655-9667
25. Russi T.J., Hirschowitz E.A., and Crystal R.G. Delayed-type hypersensitivity response to high doses of adenoviral vectors. Hum. Gene Ther. 8 (1997) 323-330
26. +CTLs in vivo. J. Immunol. 155 (1995) 2564-2570
27. Yang Y., Xiang Z., Ertl H.C., and Wilson J.M. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 92 (1995) 7257-7261
28. Todryk S., et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol. 163 (1999) 1398-1408
29. Simon R.H., et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum. Gene Ther. 4 (1993) 771-780
30. Flomenberg P., Piaskowski V., Truitt R.L., and Casper J.T. Characterization of human proliferative T cell responses to adenovirus. J. Infect. Dis. 171 (1995) 1090-1096
31. Gahery-Segard H., et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer: longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest. 100 (1997) 2218-2226
32. Elkon K.B., et al. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc. Natl. Acad. Sci. USA 94 (1997) 9814-9819
33. Benihoud K., et al. Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha. J. Virol. 72 (1998) 9514-9525
34. Minter R.M., et al. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung. J. Immunol. 164 (2000) 443-451
35. Zhang H.G., Zhou T., Yang P., Edwards III C.K., Curiel D.T., and Mountz J.D. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum. Gene Ther. 9 (1998) 1875-1884
36. Peng Y., et al. Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. J. Virol. 73 (1999) 5098-5109
37. Trevejo J.M., et al. TNF-alpha-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc. Natl. Acad. Sci. USA 98 (2001) 12162-12167
38. Philpott N.J., Nociari M., Elkon K.B., and Falck-Pedersen E. Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc. Natl. Acad. Sci. USA 101 (2004) 6200-6205
39. Echtenacher B., Falk W., Mannel D.N., and Krammer P.H. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145 (1990) 3762-3766
40. Obermeier F., Kojouharoff G., Hans W., Scholmerich J., Gross V., and Falk W. Interferon-gamma (IFN-gamma)-and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol. 116 (1999) 238-245
41. Fasbender A., Lee J.H., Walters R.W., Moninger T.O., Zabner J., and Welsh M.J. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J. Clin. Invest. 102 (1998) 184-193